FILTER

FILTERED INTERVIEW RESULTS

Italy
Pharma & Life Sciences

Giovanni Mariani

CEO, LISAPHARMA
Italy Life Sciences 2021 - Digital Interactive
Lisapharma describes the challenges Italian pharma producers have experienced over the past two years.
Italy
Pharma & Life Sciences

Rocco Pavese

CEO, GENETIC SPA
Genetic is an Italian CDMO founded in 2007 dedicated to the research and development, manufacturing, licensing-out and marketing of medicines.
Italy
Pharma & Life Sciences

Alessia Valducci

CEO, VALPHARMA
Valpharma is an Italian CMO involved in pharmaceutical development and contract manufacturing specializing in solid oral dosage medicines and nutraceuticals, both developed with modified-release technologies.
Italy
Pharma & Life Sciences

Pasquale de Blasio

FOUNDER, INTEGRATED SYSTEMS ENGINEERING (ISE)
Integrated Systems Engineering sets out its objectives to develop its TMA technology and move it into diagnostics and to build a biobank of organoids.
Italy
Pharma & Life Sciences

Massimo Versace

COUNTRY MANAGER, SUN PHARMA ITALY
Sun Pharma discusses its’ operations in Italy.
Italy
Pharma & Life Sciences

Giorgio Palu

PRESIDENT, AIFA
The Italian Medical Agency (AIFA) explains the current issues facing Italy’s life science industry.
Italy
Pharma & Life Sciences

Pierfrancesco Morosini

CEO, ICROM
Icrom is an Italian CDMO leader for the production of APIs and GMP intermediates.
Italy
Pharma & Life Sciences

Federico Chinni

MANAGING DIRECTOR, UCB ITALY
UCB Italy explains the specifications of the Italian health and pharma sector.
Italy
Pharma & Life Sciences

Fabrizio Chines

CHAIRMAN & CEO, SIFI GROUP
SIFI Group explains its pipeline and its plans for expansion in the ophthalmology space.
Italy
Pharma & Life Sciences

Maurizio Sartorato

CEO BIDACHEM SPA
Bidechem SPA explains its strategy for sustainable business growth.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL